Who makes Dose dense AC-P?

Dose dense AC-P is developed by Ottawa Hospital Research Institute.

What development phase is Dose dense AC-P in?

Dose dense AC-P is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Dose dense AC-P

Ottawa Hospital Research Institute · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Dose dense AC-P
Also known as	doxorubicin, cyclophosphamide, paclitaxel
Sponsor	Ottawa Hospital Research Institute
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (PHASE4)
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility (PHASE2)
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency (PHASE3)
Fasting on Newly Diagnosed Breast Cancer (PHASE1, PHASE2)
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dose dense AC-P CI brief — competitive landscape report
Dose dense AC-P updates RSS · CI watch RSS
Ottawa Hospital Research Institute portfolio CI